Veracyte, Inc.
DE ˙ DB ˙ US92337F1075
40,53 € ↓ -2,45 (-5,70%)
2026-06-05
DEL PRIS
SecurityDE:12V / Veracyte, Inc.
InstitutionGoldman Sachs Group Inc
Latest Disclosed Ownership1,276,260 shares
Latest Disclosed Value $ 41,108,335
Goldman Sachs Group Inc reports 6.86% increase in ownership of 12V / Veracyte, Inc.

On May 15, 2026 - Goldman Sachs Group Inc filed a 13F-HR form disclosing ownership of 1,276,260 shares of Veracyte, Inc. (DE:12V) valued at $33,948,516 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 1,194,327 shares of Veracyte, Inc.. This represents a change in shares of 6.86% during the quarter. The current value of the position is $51,726,818 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERACYTE CMN 92337F107 1,276,260 81,933 6.86 41,108 -18.24 0.0011
2026-02-10 2025-12-31 13F VERACYTE CMN 92337F107 1,194,327 -145,836 -10.88 50,281 9.29 0.0062
2025-11-14 2025-09-30 13F VERACYTE CMN 92337F107 1,340,163 -208,311 -13.45 46,008 9.92 0.0056
2025-08-14 2025-06-30 13F VERACYTE CMN 92337F107 1,548,474 499,826 47.66 41,855 34.62 0.0057
2025-06-27 2025-03-31 13F/A-2 VERACYTE CMN 92337F107 1,048,648 -167,824 -13.80 31,092 -35.46 0.0050
2025-05-16 2025-03-31 13F/A-1 VERACYTE CMN 92337F107 1,048,648 -167,824 31,092 0.0013
2025-05-09 2025-03-31 13F VERACYTE CMN 92337F107 1,048,648 -167,824 31,092 0.0009
2025-02-11 2024-12-31 13F VERACYTE CMN 92337F107 1,216,472 -97,022 -7.39 48,172 7.74 0.0076
2024-11-14 2024-09-30 13F VERACYTE CMN 92337F107 1,313,494 222,294 20.37 44,711 89.08 0.0072
2024-08-13 2024-06-30 13F VERACYTE CMN 92337F107 1,091,200 114,111 11.68 23,646 9.21 0.0040
2024-05-15 2024-03-31 13F VERACYTE CMN 92337F107 977,089 -238,857 -19.64 21,652 -35.27 0.0038
2024-05-14 2023-12-31 13F/A-2 VERACYTE CMN 92337F107 1,215,946 -90,216 -6.91 33,451 14.69 0.0062
2024-03-01 2023-12-31 13F/A-1 VERACYTE CMN 92337F107 1,215,946 33,451
2024-02-13 2023-12-31 13F VERACYTE CMN 92337F107 1,215,946 -90,216 33,451 0.0011
2024-05-15 2023-09-30 13F/A-1 VERACYTE CMN 92337F107 1,306,162 37,551 2.96 29,167 -9.73 0.0062
2023-11-14 2023-09-30 13F VERACYTE CMN 92337F107 1,306,162 37,551 29,167 0.0059
2024-05-14 2023-06-30 13F/A-1 VERACYTE CMN 92337F107 1,268,611 -146,152 -10.33 32,312 2.42 0.0069
2023-08-15 2023-06-30 13F VERACYTE CMN 92337F107 1,268,611 -146,152 32,312 0.0065
2024-05-14 2023-03-31 13F/A-1 VERACYTE CMN 92337F107 1,414,763 196,974 16.17 31,549 9.17 0.0072
2023-05-11 2023-03-31 13F VERACYTE CMN 92337F107 1,414,763 196,974 31,549 0.0067
2024-05-14 2022-12-31 13F/A-1 VERACYTE CMN 92337F107 1,217,789 -110,740 -8.34 28,898 131,254.55 0.0071
2023-02-13 2022-12-31 13F VERACYTE CMN 92337F107 1,217,789 -110,740 28,898 0.0065
2024-05-14 2022-09-30 13F/A-1 VERACYTE CMN 92337F107 1,328,529 278,684 26.55 22 10.00 0.0056
2022-11-14 2022-09-30 13F VERACYTE CMN 92337F107 1,328,529 278,684 22,054 0.0051
2024-05-14 2022-06-30 13F/A-2 VERACYTE CMN 92337F107 1,049,845 575,949 121.53 21 -99.85 0.0052
2022-08-18 2022-06-30 13F/A-1 VERACYTE CMN 92337F107 1,049,845 575,949 20,892 0.0047
2022-08-15 2022-06-30 13F VERACYTE CMN 92337F107 1,049,845 575,949 20,892 0.0047
2022-05-16 2022-03-31 13F VERACYTE CMN 92337F107 473,896 58,195 14.00 13,065 -23.71 0.0027
2022-02-17 2021-12-31 13F/A-1 VERACYTE CMN 92337F107 415,701 17,286 4.34 17,126 -7.46 0.0034
2022-02-14 2021-12-31 13F VERACYTE CMN 92337F107 415,701 17,286 17,126 0.0010
2022-01-20 2021-09-30 13F/A-1 VERACYTE CMN 92337F107 398,415 -383,859 -49.07 18,506 -40.83 0.0039
2021-11-10 2021-09-30 13F VERACYTE CMN 92337F107 398,415 -383,859 18,506 0.0011
2021-08-13 2021-06-30 13F VERACYTE CMN 92337F107 782,274 -175,203 -18.30 31,275 -39.23 0.0070
2021-05-17 2021-03-31 13F VERACYTE CMN 92337F107 957,477 428,450 80.99 51,464 98.77 0.0130
2021-02-12 2020-12-31 13F VERACYTE CMN 92337F107 529,027 187,010 54.68 25,891 133.00 0.0067
2020-11-13 2020-09-30 13F VERACYTE CMN 92337F107 342,017 51,489 17.72 11,112 47.69 0.0032
2020-08-12 2020-06-30 13F VERACYTE CMN 92337F107 290,528 -499,772 -63.24 7,524 -60.84 0.0023
2020-05-15 2020-03-31 13F VERACYTE CMN 92337F107 790,300 83,208 11.77 19,212 -2.68 0.0068
2020-02-14 2019-12-31 13F VERACYTE CMN 92337F107 707,092 -61,518 -8.00 19,741 7.02 0.0050
2019-11-14 2019-09-30 13F VERACYTE CMN 92337F107 768,610 44,231 6.11 18,446 -10.68 0.0053
2019-08-14 2019-06-30 13F VERACYTE CMN 92337F107 724,379 -201,920 -21.80 20,652 -10.89 0.0059
2019-05-15 2019-03-31 13F VERACYTE CMN 92337F107 926,299 194,232 26.53 23,176 151.67 0.0070
2019-02-14 2018-12-31 13F VERACYTE CMN 92337F107 732,067 -15,846 -2.12 9,209 28.92 0.0029
2018-11-14 2018-09-30 13F VERACYTE CMN 92337F107 747,913 674,061 912.72 7,143 935.22 0.0018
2018-08-14 2018-06-30 13F VERACYTE CMN 92337F107 73,852 33,794 84.36 690 209.42 0.0002
2018-05-15 2018-03-31 13F VERACYTE CMN 92337F107 40,058 -10,114 -20.16 223 -32.01 0.0001
2018-02-14 2017-12-31 13F VERACYTE CMN 92337F107 50,172 21,088 72.51 328 28.63 0.0001
2017-11-14 2017-09-30 13F VERACYTE CMN 92337F107 29,084 -14,483 -33.24 255 -29.75 0.0001
2017-08-14 2017-06-30 13F VERACYTE CMN 92337F107 43,567 29,997 221.05 363 190.40 0.0001
2017-05-18 2017-03-31 13F/A-1 VERACYTE CMN 92337F107 13,570 -2,969 -17.95 125 -2.34 0.0000
2017-05-15 2017-03-31 13F VERACYTE CMN 92337F107 13,570 125
2017-02-14 2016-12-31 13F VERACYTE CMN 92337F107 16,539 16,539 0.00 128 0.0000
2016-11-14 2016-09-30 13F VERACYTE CMN 92337F107 0 -10,970 -100.00 0 -100.00
2016-08-15 2016-06-30 13F VERACYTE CMN 92337F107 10,970 10,970 0.00 55 0.0000
2016-05-13 2016-03-31 13F VERACYTE CMN 92337F107 0 -63,084 -100.00 0 -100.00
2016-02-16 2015-12-31 13F VERACYTE CMN 92337F107 63,084 14,491 29.82 454 99.12 0.0001
2015-11-13 2015-09-30 13F VERACYTE CMN 92337F107 48,593 9,565 24.51 228 -47.59 0.0001
2015-08-14 2015-06-30 13F VERACYTE CMN 92337F107 39,028 14,648 60.08 435 145.76 0.0001
2015-05-15 2015-03-31 13F VERACYTE CMN 92337F107 24,380 24,380 0.00 177 0.0001
2014-11-14 2014-09-30 13F VERACYTE CMN 92337F107 0 -10,308 -100.00 0 -100.00
2014-08-14 2014-06-30 13F VERACYTE CMN 92337F107 10,308 10,308 176 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.